Impact of adding carboplatin to docetaxel chemotherapy on testosterone levels and treatment outcomes in metastatic docetaxel-resistant prostate cancer
Abstract Docetaxel resistance, particularly post-androgen-receptor targeted therapy (ART), undermines its clinical utility in metastatic castration-resistant prostate cancer (mCRPC). This study explores the impact of docetaxel plus carboplatin (DC) chemotherapy on serum testosterone levels in metast...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-06-01
|
| Series: | Scientific Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1038/s41598-025-04667-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849686083790438400 |
|---|---|
| author | Hejar Atalan Michael A. Morgan Philipp Ivanyi Paula Kappler Florian H. Heidel Christoph W. M. Reuter |
| author_facet | Hejar Atalan Michael A. Morgan Philipp Ivanyi Paula Kappler Florian H. Heidel Christoph W. M. Reuter |
| author_sort | Hejar Atalan |
| collection | DOAJ |
| description | Abstract Docetaxel resistance, particularly post-androgen-receptor targeted therapy (ART), undermines its clinical utility in metastatic castration-resistant prostate cancer (mCRPC). This study explores the impact of docetaxel plus carboplatin (DC) chemotherapy on serum testosterone levels in metastatic docetaxel-resistant prostate cancer (mDRPC) patients. 123 mDRPC patients were categorized into three groups: (1) no previous ART (n = 65), (2) previous ART with serum free testosterone (FT) > detection limit (DL) at baseline (n = 31), and (3) previous ART with FT < DL at baseline (n = 27). Salvage DC chemotherapy led to significant reductions in FT and total testosterone (TT) levels in groups 1 and 2 (p < 0.05). Group 1 saw FT decrease from 0.85 pg/mL to below the DL (< 0.18 pg/mL) with 54.3% achieving complete reduction (CR); group 2 showed FT decrease from 0.28 pg/mL to below the DL with 67.7% achieving CR; group 3 had baseline FT values already below the DL with 96.3% maintaining this level. TT reductions to below the DL occurred in all groups. Low FT was an independent predictor for better PFS and for improved OS in groups 1 and 2. Our data indicate that adding carboplatin may improve the therapeutic effects of docetaxel in a castration-dependent setting. |
| format | Article |
| id | doaj-art-2b065e661983416f87d8ee40b088eca1 |
| institution | DOAJ |
| issn | 2045-2322 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj-art-2b065e661983416f87d8ee40b088eca12025-08-20T03:22:50ZengNature PortfolioScientific Reports2045-23222025-06-0115111510.1038/s41598-025-04667-0Impact of adding carboplatin to docetaxel chemotherapy on testosterone levels and treatment outcomes in metastatic docetaxel-resistant prostate cancerHejar Atalan0Michael A. Morgan1Philipp Ivanyi2Paula Kappler3Florian H. Heidel4Christoph W. M. Reuter5Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical SchoolInstitute of Experimental Hematology, Hannover Medical SchoolDepartment of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical SchoolDepartment of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical SchoolDepartment of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical SchoolDepartment of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical SchoolAbstract Docetaxel resistance, particularly post-androgen-receptor targeted therapy (ART), undermines its clinical utility in metastatic castration-resistant prostate cancer (mCRPC). This study explores the impact of docetaxel plus carboplatin (DC) chemotherapy on serum testosterone levels in metastatic docetaxel-resistant prostate cancer (mDRPC) patients. 123 mDRPC patients were categorized into three groups: (1) no previous ART (n = 65), (2) previous ART with serum free testosterone (FT) > detection limit (DL) at baseline (n = 31), and (3) previous ART with FT < DL at baseline (n = 27). Salvage DC chemotherapy led to significant reductions in FT and total testosterone (TT) levels in groups 1 and 2 (p < 0.05). Group 1 saw FT decrease from 0.85 pg/mL to below the DL (< 0.18 pg/mL) with 54.3% achieving complete reduction (CR); group 2 showed FT decrease from 0.28 pg/mL to below the DL with 67.7% achieving CR; group 3 had baseline FT values already below the DL with 96.3% maintaining this level. TT reductions to below the DL occurred in all groups. Low FT was an independent predictor for better PFS and for improved OS in groups 1 and 2. Our data indicate that adding carboplatin may improve the therapeutic effects of docetaxel in a castration-dependent setting.https://doi.org/10.1038/s41598-025-04667-0Prostate cancerDocetaxel resistanceCarboplatinTestosterone |
| spellingShingle | Hejar Atalan Michael A. Morgan Philipp Ivanyi Paula Kappler Florian H. Heidel Christoph W. M. Reuter Impact of adding carboplatin to docetaxel chemotherapy on testosterone levels and treatment outcomes in metastatic docetaxel-resistant prostate cancer Scientific Reports Prostate cancer Docetaxel resistance Carboplatin Testosterone |
| title | Impact of adding carboplatin to docetaxel chemotherapy on testosterone levels and treatment outcomes in metastatic docetaxel-resistant prostate cancer |
| title_full | Impact of adding carboplatin to docetaxel chemotherapy on testosterone levels and treatment outcomes in metastatic docetaxel-resistant prostate cancer |
| title_fullStr | Impact of adding carboplatin to docetaxel chemotherapy on testosterone levels and treatment outcomes in metastatic docetaxel-resistant prostate cancer |
| title_full_unstemmed | Impact of adding carboplatin to docetaxel chemotherapy on testosterone levels and treatment outcomes in metastatic docetaxel-resistant prostate cancer |
| title_short | Impact of adding carboplatin to docetaxel chemotherapy on testosterone levels and treatment outcomes in metastatic docetaxel-resistant prostate cancer |
| title_sort | impact of adding carboplatin to docetaxel chemotherapy on testosterone levels and treatment outcomes in metastatic docetaxel resistant prostate cancer |
| topic | Prostate cancer Docetaxel resistance Carboplatin Testosterone |
| url | https://doi.org/10.1038/s41598-025-04667-0 |
| work_keys_str_mv | AT hejaratalan impactofaddingcarboplatintodocetaxelchemotherapyontestosteronelevelsandtreatmentoutcomesinmetastaticdocetaxelresistantprostatecancer AT michaelamorgan impactofaddingcarboplatintodocetaxelchemotherapyontestosteronelevelsandtreatmentoutcomesinmetastaticdocetaxelresistantprostatecancer AT philippivanyi impactofaddingcarboplatintodocetaxelchemotherapyontestosteronelevelsandtreatmentoutcomesinmetastaticdocetaxelresistantprostatecancer AT paulakappler impactofaddingcarboplatintodocetaxelchemotherapyontestosteronelevelsandtreatmentoutcomesinmetastaticdocetaxelresistantprostatecancer AT florianhheidel impactofaddingcarboplatintodocetaxelchemotherapyontestosteronelevelsandtreatmentoutcomesinmetastaticdocetaxelresistantprostatecancer AT christophwmreuter impactofaddingcarboplatintodocetaxelchemotherapyontestosteronelevelsandtreatmentoutcomesinmetastaticdocetaxelresistantprostatecancer |